Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies

被引:168
作者
Saber, W. [1 ]
Moua, T. [1 ]
Williams, E. C. [1 ]
Verso, M. [2 ]
Agnelli, G. [2 ]
Couban, S. [3 ]
Young, A. [4 ]
de Cicco, M. [5 ]
Biffi, R. [6 ]
van Rooden, C. J. [7 ]
Huisman, M. V. [7 ]
Fagnani, D.
Cimminiello, C.
Moia, M.
Magagnoli, M. [8 ]
Povoski, S. P. [9 ,10 ,11 ]
Malak, S. F. [12 ]
Lee, A. Y. [13 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Univ & Hosp Perugia, Perugia, Italy
[3] Queen Elizabeth II Hlth, Ctr Sci, Halifax, NS, Canada
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Natl Canc Inst, Ctr Riferimento Oncol, Aviano, PN, Italy
[6] European Inst Oncol, Milan, Italy
[7] Leiden Univ, Leiden, Netherlands
[8] Ist Clin Humanitas, Milan, Italy
[9] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[10] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA
[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[12] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA
[13] Univ British Columbia, Diamond Hlth Care Ctr, Div Hematol, Vancouver, BC V5Z 1M9, Canada
关键词
adults; cancer; catheter-related thrombosis; meta-analysis; risk factors; thromboprophylaxis; CENTRAL VENOUS CATHETER; SUBCLAVIAN VEIN-THROMBOSIS; FACTOR-V-LEIDEN; HEMATOLOGICAL MALIGNANCIES; DOSE WARFARIN; DOUBLE-BLIND; PREVENTION; COMPLICATIONS; PROPHYLAXIS; MULTICENTER;
D O I
10.1111/j.1538-7836.2010.04126.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Knowledge of independent, baseline risk factors for catheter-related thrombosis (CRT) may help select adult cancer patients who are at high risk to receive thromboprophylaxis. Objectives: We conducted a meta-analysis of individual patient-level data to identify these baseline risk factors. Patients/Methods: MEDLINE, EMBASE, CINAHL, CENTRAL, DARE and the Grey literature databases were searched in all languages from 1995 to 2008. Prospective studies and randomized controlled trials (RCTs) were eligible. Studies were included if original patient-level data were provided by the investigators and if CRT was objectively confirmed with valid imaging. Multivariate logistic regression analysis of 17 prespecified baseline characteristics was conducted. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Results: A total sample of 5636 subjects from five RCTs and seven prospective studies was included in the analysis. Among these subjects, 425 CRT events were observed. In multivariate logistic regression, the use of implanted ports as compared with peripherally implanted central venous catheters (PICCs), decreased CRT risk (OR, 0.43; 95% CI, 0.23-0.80), whereas past history of deep vein thrombosis (DVT) (OR, 2.03; 95% CI, 1.05-3.92), subclavian venipuncture insertion technique (OR, 2.16; 95% CI, 1.07-4.34) and improper catheter tip location (OR, 1.92; 95% CI, 1.22-3.02), increased CRT risk. Conclusions: CRT risk is increased with use of PICCs, previous history of DVT, subclavian venipuncture insertion technique and improper positioning of the catheter tip. These factors may be useful for risk stratifying patients to select those for thromboprophylaxis. Prospective studies are needed to validate these findings.
引用
收藏
页码:312 / 319
页数:8
相关论文
共 38 条
[1]   Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients [J].
Abdelkefi, A ;
Ben Romdhane, N ;
Kriaa, A ;
Chelli, M ;
Torjman, L ;
Ladeb, S ;
Ben Othman, T ;
Lakhal, A ;
Guermazi, S ;
Ben Hassen, A ;
Ladeb, F ;
Ben Abdeladhim, A .
BONE MARROW TRANSPLANTATION, 2005, 36 (10) :885-889
[2]   VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL [J].
BERN, MM ;
LOKICH, JJ ;
WALLACH, SR ;
BOTHE, A ;
BENOTTI, PN ;
ARKIN, CF ;
GRECO, FA ;
HUBERMAN, M ;
MOORE, C .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :423-428
[3]   Upper extremity deep venous thrombosis [J].
Bernardi, Enrico ;
Pesavento, Raffaele ;
Prandoni, Paolo .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (07) :729-736
[4]  
Biffi R, 2001, CANCER, V92, P1204, DOI 10.1002/1097-0142(20010901)92:5<1204::AID-CNCR1439>3.0.CO
[5]  
2-9
[6]   Central venous catheter-related complications in patients with hematological malignancies: A retrospective analysis of risk factors and prophylactic measures [J].
Cortelezza, A ;
Fracchiolla, NS ;
Maisonneuve, P ;
Moia, M ;
Luchesini, C ;
Ranzi, ML ;
Monni, P ;
Pasquini, MC ;
Lambertenghi-Deliliers, G .
LEUKEMIA & LYMPHOMA, 2003, 44 (09) :1495-1501
[7]   Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study [J].
Cortelezzi, A ;
Moia, M ;
Falanga, A ;
Pogliani, EM ;
Agnelli, G ;
Bonizzoni, E ;
Gussoni, G ;
Barbui, T ;
Mannucci, PM .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :811-817
[8]   Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer [J].
Couban, S ;
Goodyear, M ;
Burnell, M ;
Dolan, S ;
Wasi, P ;
Barnes, D ;
MacLeod, D ;
Burton, E ;
Andreou, P ;
Anderson, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4063-4069
[9]  
De Cicco M, 2006, J CLIN ONCOL, V24, p480S
[10]  
Eastman ME, 2001, CANCER-AM CANCER SOC, V91, P806, DOI 10.1002/1097-0142(20010215)91:4<806::AID-CNCR1068>3.3.CO